Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Profit After Tax (2016 - 2025)

Sangamo Therapeutics has reported Profit After Tax over the past 16 years, most recently at -$37.4 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$37.4 million for Q4 2025, down 59.94% from a year ago — trailing twelve months through Dec 2025 was -$122.9 million (down 25.52% YoY), and the annual figure for FY2025 was -$122.9 million, down 25.52%.
  • Profit After Tax for Q4 2025 was -$37.4 million at Sangamo Therapeutics, down from -$34.9 million in the prior quarter.
  • Over the last five years, Profit After Tax for SGMO hit a ceiling of $21.1 million in Q1 2023 and a floor of -$114.5 million in Q2 2023.
  • Median Profit After Tax over the past 5 years was -$43.6 million (2022), compared with a mean of -$42.5 million.
  • Biggest five-year swings in Profit After Tax: tumbled 3062.33% in 2021 and later surged 148.05% in 2023.
  • Sangamo Therapeutics' Profit After Tax stood at -$37.5 million in 2021, then plummeted by 38.61% to -$52.0 million in 2022, then dropped by 16.01% to -$60.3 million in 2023, then skyrocketed by 61.2% to -$23.4 million in 2024, then plummeted by 59.94% to -$37.4 million in 2025.
  • The last three reported values for Profit After Tax were -$37.4 million (Q4 2025), -$34.9 million (Q3 2025), and -$20.0 million (Q2 2025) per Business Quant data.